Oncology Central

NICE approves atezolizumab for advanced bladder cancer patients on the NHS

Patients with advanced bladder cancer whose disease has progressed during or after treatment with platinum-containing chemotherapy, can now access Tecentriq® (atezolizumab) via routine NHS funding in England and Wales.

The approval is based on the totality of evidence from the Phase II/III IMvigor210 and IMvigor211 studies, which demonstrated the clinical efficacy and safety of atezolizumab compared with therapies currently provided to patients in this setting.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.